We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $10.1B
1-Year Est. Return 42.88%
This Fund
S&P 500
This Quarter Est. Return
-27.19%
1 Year Est. Return
+42.88%
3 Year Est. Return
+92.52%
5 Year Est. Return
+113.84%
10 Year Est. Return
+608.05%
AUM
$7.34B
AUM Growth
-$3.86B
Cap. Flow
-$375M
Cap. Flow %
-5.12%
Top 10 Hldgs %
9.89%
Holding
1,223
New
86
Increased
388
Reduced
436
Closed
75

Top Buys

Rank Stock Value
1
ESE icon
ESCO Technologies
ESE
+$40.8M
2
HAE icon
Haemonetics
HAE
+$37.6M
3
ROG icon
Rogers Corp
ROG
+$26.2M
4
EVR icon
Evercore
EVR
+$25.5M
5
FARO
Faro Technologies
FARO
+$22M

Sector Composition

Rank Sector Weight
1 Industrials 25.72%
2 Technology 19.64%
3 Financials 14.17%
4 Consumer Discretionary 10.37%
5 Healthcare 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HPR
1026
DELISTED
HighPoint Resources Corporation
HPR
$44K ﹤0.01%
4,651
+1,639
+54% +$73K
AAMI
1027
Acadian Asset Management
AAMI
$3.08B
$43K ﹤0.01%
6,728
+1,536
+30% +$13.3K
CVLT icon
1028
Commault Systems
CVLT
$4.88B
$42K ﹤0.01%
1,026
+72
+8% +$3.11K
LRN icon
1029
Stride
LRN
$3.41B
$42K ﹤0.01%
2,236
-285
-11% -$5.26K
NUVA
1030
DELISTED
NuVasive, Inc.
NUVA
$42K ﹤0.01%
+823
New +$55.2K
IRBT
1031
DELISTED
iRobot
IRBT
$41K ﹤0.01%
+1,008
New +$48.4K
MYGN icon
1032
Myriad Genetics
MYGN
$270M
$41K ﹤0.01%
2,870
+796
+38% +$16.8K
NWLI
1033
DELISTED
National Western Life Group, Inc. Class A
NWLI
$41K ﹤0.01%
238
-20
-8% -$4.9K
ARNA
1034
DELISTED
Arena Pharmaceuticals Inc
ARNA
$41K ﹤0.01%
981
-117
-11% -$5.36K
SYKE
1035
DELISTED
SYKES Enterprises Inc
SYKE
$40K ﹤0.01%
1,471
-31
-2% -$1K
SYNA icon
1036
Synaptics
SYNA
$4.19B
$39K ﹤0.01%
675
-272
-29% -$18.4K
CURO
1037
DELISTED
CURO Group Holdings Corp.
CURO
$39K ﹤0.01%
+7,444
New +$71.1K
PAHC icon
1038
Phibro Animal Health
PAHC
$1.47B
$38K ﹤0.01%
1,565
-292
-16% -$7.14K
STR
1039
DELISTED
Sitio Royalties
STR
$38K ﹤0.01%
4,437
+2,407
+119% +$43.3K
WTTR icon
1040
Select Water Solutions
WTTR
$2.3B
$37K ﹤0.01%
11,349
+5,426
+92% +$34.5K
HEES
1041
DELISTED
H&E Equipment Services
HEES
$36K ﹤0.01%
2,463
+840
+52% +$20.3K
DNOW icon
1042
DNOW Inc
DNOW
$2.58B
$35K ﹤0.01%
6,879
+1,565
+29% +$14.1K
GNE icon
1043
Genie Energy
GNE
$367M
$35K ﹤0.01%
4,911
+827
+20% +$5.95K
HBT icon
1044
HBT Financial
HBT
$1.3B
$35K ﹤0.01%
3,348
+359
+12% +$5.89K
MMSI icon
1045
Merit Medical Systems
MMSI
$5.08B
$35K ﹤0.01%
1,121
-114,512
-99% -$4.08M
SBH icon
1046
Sally Beauty Holdings
SBH
$1.43B
$35K ﹤0.01%
4,298
+1,075
+33% +$14.3K
CPE
1047
DELISTED
Callon Petroleum Company
CPE
$35K ﹤0.01%
6,325
DCOM
1048
DELISTED
Dime Community Bancshares
DCOM
$35K ﹤0.01%
2,577
-4,630
-64% -$82.1K
HDSN
1049
Hudson Technologies
HDSN
$254M
$34K ﹤0.01%
50,000
OFLX icon
1050
Omega Flex
OFLX
$297M
$34K ﹤0.01%
401
+50
+14% +$4.54K

Similar funds

Royce & Associates's Q1 2020 Portfolio in Review

As of Q1 2020, Royce & Associates held 1,223 positions worth $7.34B, down 34% from $11.2B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.

Royce & Associates withdrew a net $375M in Q1 2020, closing 75 positions and reducing 436 holdings. Its most notable exit was AVX Corporation, an estimated $71.1M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.

Against the trend, Royce & Associates opened a new position in ESCO Technologies worth $33.9M.

  • Royce & Associates's largest Q1 2020 buy was ESCO Technologies: 447,118 shares worth $33.9M.
  • Royce & Associates added most to Haemonetics in Q1 2020, an estimated $37.6M increase.
  • Royce & Associates's biggest Q1 2020 reduction was Virtu Financial, cutting an estimated $51M.
  • Royce & Associates fully exited AVX Corporation in Q1 2020, selling an estimated $71.1M.
  • Royce & Associates's ten largest holdings make up 9.9% of its $7.34B portfolio in Q1 2020.
  • Royce & Associates opened 86 new positions and closed 75 in Q1 2020.
  • Royce & Associates's portfolio value fell 34% quarter-over-quarter to $7.34B.

Based on Royce & Associates's 13F filing for Q1 2020, filed 12 May 2020.